MAP2K7 and urinary bladder neoplasm: Additional preclinical work is warranted to assess the impact of dual mTOR-PI3K and MEK-PI3K inhibition on a large panel of UC cell lines with a range of PI3K/AKT and MEK/ERK pathway genetic alterations to fully understand the context for optimal therapy of PI3K pathway-dependent bladder tumors.